Drug Trial Radar · NCT04770545
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
792
Actual
Start
Mar 4, 2021
Primary completion
Sep 5, 2025
Study completion Sep 5, 2025
Sponsor
- Lead sponsor
- Apellis Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).
Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
PEGCETACOPLAN (APL-2)Drug
Complement (C3) Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced at Least One Ocular and Systemic Adverse Events (AEs)Time frame: From Day 1 up to Month 36
Locations
175 sites in 15 countries. Site status is shown where the registry gives one.
Retinal Research Institute, LLC
Phoenix, Arizona
Associated Retina Consultants, Ltd.
Phoenix, Arizona
California Retina Consultants
Bakersfield, California
Retinal Diagnostic Center
Campbell, California
The Retina Partners
Encino, California
Retina Consultants of Orange County
Fullerton, California
Atlantis Eyecare
Huntington Beach, California
Jacobs Retina Center, UCSD
La Jolla, California
Doheny Eye Center UCLA
Los Angeles, California
Northern California Retina Vitreous Associates
Mountain View, California
Retina Institute of California Medical Group
Palm Desert, California
Byers Eye Institute, Stanford University
Palo Alto, California
Retina Consultants San Diego
Poway, California
Orange County Retina Medical Group
Santa Ana, California
California Retina Consultants
Santa Barbara, California
Bay Area Retina Associates
Walnut Creek, California
Southwest Retina Research Center, LLC
Durango, Colorado
Danbury Eye Physicians & Surgeons, PC
Danbury, Connecticut
Retina Group of New England - New London
Waterford, Connecticut
Florida Eye Microsurgical Institute, Inc.
Boynton Beach, Florida
Blue Ocean Clinical Research
Clearwater, Florida
Pinnacle Research Institute
Fort Lauderdale, Florida
Retina Health Center
Fort Myers, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Bascom Palmer Eye Institute
Miami, Florida
Bascom Palmer Eye Institute at Naples
Naples, Florida
Palm Beach Gardens
Palm Beach Gardens, Florida
Retina Specialty Institute
Pensacola, Florida
Eye Associates of Pinellas
Pinellas Park, Florida
East Florida Eye Institute
Stuart, Florida
Retina Associates of Florida
Tampa, Florida
University of South Florida
Tampa, Florida
Center for Retina and Macular Disease
Winter Haven, Florida
Southeast Retina Center, PC
Augusta, Georgia
Georgia Retina, PC
Marietta, Georgia
Gailey Eye Clinic Retina Center
Bloomington, Illinois
Northwestern Feinberg School of Medicine
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Midwest Eye Institute
Indianapolis, Indiana
Retina and Vitreous Associates of Kentucky, PSC dba Retina Associates of Kentucky
Lexington, Kentucky
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.